An Assessment of the State of Current Practice in Coagulation Laboratories

Nicole D. Zantek, Catherine P M Hayward, Trevor G. Simcox, Kristi J. Smock, Peihong Hsu, Elizabeth M. Van Cott

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: To assess the state of current practice in coagulation laboratories regarding three pressing issues: staffing, handling Ebola specimens, and testing/billing for tests that measure direct oral anticoagulants (DOAC). Methods: A survey and analysis of specialized coagulation laboratories in North America was conducted. Results: Approximately 4,000 special coagulation tests-per-technologist-per-year was rated as either a "good" staffing level or "adequate-but-ideally-need-more" employees. Requiring technologists to perform more than that was rated as an "inadequate" staffing level. For Ebola patients, coagulation testing is mostly performed by point-of-care. Only 26.1% would perform coagulation tests for Ebola specimens within their laboratory (rather than at the bed side or a separate designated space outside the laboratory). Coagulation tests offered for Ebola patients were limited: prothrombin time (63.0% of laboratories), activated partial thromboplastin time (37.0%), D-dimer (13.0%), and fibrinogen (8.7%); 26.1% of laboratories did not offer any coagulation tests for Ebola patients. Approximately 35% of special coagulation laboratories bill for at least one laboratory test for DOACs: 33% bill for an anti-Xa calibrated with rivaroxaban, 17% bill for an anti-Xa calibrated with apixaban, and 27% bill for at least one of several tests for dabigatran. Approximately 48% do not offer any tests for DOACs. Conclusions: These results may help laboratories negotiate for additional technologists if needed, prepare for Ebola specimens, and manage the demand for laboratory tests for new DOAC anticoagulants.

Original languageEnglish (US)
Pages (from-to)378-383
Number of pages6
JournalAmerican Journal of Clinical Pathology
Volume146
Issue number3
DOIs
StatePublished - Sep 1 2016

Fingerprint

Anticoagulants
Point-of-Care Systems
Specimen Handling
Partial Thromboplastin Time
Prothrombin Time
North America
Fibrinogen
Surveys and Questionnaires
apixaban
Dabigatran
Rivaroxaban
fibrin fragment D

Keywords

  • Apixaban
  • Dabigatran
  • Direct oral anticoagulant (DOAC)
  • Ebola
  • Rivaroxaban
  • Specialized coagulation laboratory
  • Staffing

PubMed: MeSH publication types

  • Journal Article

Cite this

An Assessment of the State of Current Practice in Coagulation Laboratories. / Zantek, Nicole D.; Hayward, Catherine P M; Simcox, Trevor G.; Smock, Kristi J.; Hsu, Peihong; Van Cott, Elizabeth M.

In: American Journal of Clinical Pathology, Vol. 146, No. 3, 01.09.2016, p. 378-383.

Research output: Contribution to journalArticle

Zantek, Nicole D. ; Hayward, Catherine P M ; Simcox, Trevor G. ; Smock, Kristi J. ; Hsu, Peihong ; Van Cott, Elizabeth M. / An Assessment of the State of Current Practice in Coagulation Laboratories. In: American Journal of Clinical Pathology. 2016 ; Vol. 146, No. 3. pp. 378-383.
@article{6f375e7bb8c64f9c84ae6968ea247008,
title = "An Assessment of the State of Current Practice in Coagulation Laboratories",
abstract = "Objectives: To assess the state of current practice in coagulation laboratories regarding three pressing issues: staffing, handling Ebola specimens, and testing/billing for tests that measure direct oral anticoagulants (DOAC). Methods: A survey and analysis of specialized coagulation laboratories in North America was conducted. Results: Approximately 4,000 special coagulation tests-per-technologist-per-year was rated as either a {"}good{"} staffing level or {"}adequate-but-ideally-need-more{"} employees. Requiring technologists to perform more than that was rated as an {"}inadequate{"} staffing level. For Ebola patients, coagulation testing is mostly performed by point-of-care. Only 26.1{\%} would perform coagulation tests for Ebola specimens within their laboratory (rather than at the bed side or a separate designated space outside the laboratory). Coagulation tests offered for Ebola patients were limited: prothrombin time (63.0{\%} of laboratories), activated partial thromboplastin time (37.0{\%}), D-dimer (13.0{\%}), and fibrinogen (8.7{\%}); 26.1{\%} of laboratories did not offer any coagulation tests for Ebola patients. Approximately 35{\%} of special coagulation laboratories bill for at least one laboratory test for DOACs: 33{\%} bill for an anti-Xa calibrated with rivaroxaban, 17{\%} bill for an anti-Xa calibrated with apixaban, and 27{\%} bill for at least one of several tests for dabigatran. Approximately 48{\%} do not offer any tests for DOACs. Conclusions: These results may help laboratories negotiate for additional technologists if needed, prepare for Ebola specimens, and manage the demand for laboratory tests for new DOAC anticoagulants.",
keywords = "Apixaban, Dabigatran, Direct oral anticoagulant (DOAC), Ebola, Rivaroxaban, Specialized coagulation laboratory, Staffing",
author = "Zantek, {Nicole D.} and Hayward, {Catherine P M} and Simcox, {Trevor G.} and Smock, {Kristi J.} and Peihong Hsu and {Van Cott}, {Elizabeth M.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1093/ajcp/aqw121",
language = "English (US)",
volume = "146",
pages = "378--383",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - An Assessment of the State of Current Practice in Coagulation Laboratories

AU - Zantek, Nicole D.

AU - Hayward, Catherine P M

AU - Simcox, Trevor G.

AU - Smock, Kristi J.

AU - Hsu, Peihong

AU - Van Cott, Elizabeth M.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Objectives: To assess the state of current practice in coagulation laboratories regarding three pressing issues: staffing, handling Ebola specimens, and testing/billing for tests that measure direct oral anticoagulants (DOAC). Methods: A survey and analysis of specialized coagulation laboratories in North America was conducted. Results: Approximately 4,000 special coagulation tests-per-technologist-per-year was rated as either a "good" staffing level or "adequate-but-ideally-need-more" employees. Requiring technologists to perform more than that was rated as an "inadequate" staffing level. For Ebola patients, coagulation testing is mostly performed by point-of-care. Only 26.1% would perform coagulation tests for Ebola specimens within their laboratory (rather than at the bed side or a separate designated space outside the laboratory). Coagulation tests offered for Ebola patients were limited: prothrombin time (63.0% of laboratories), activated partial thromboplastin time (37.0%), D-dimer (13.0%), and fibrinogen (8.7%); 26.1% of laboratories did not offer any coagulation tests for Ebola patients. Approximately 35% of special coagulation laboratories bill for at least one laboratory test for DOACs: 33% bill for an anti-Xa calibrated with rivaroxaban, 17% bill for an anti-Xa calibrated with apixaban, and 27% bill for at least one of several tests for dabigatran. Approximately 48% do not offer any tests for DOACs. Conclusions: These results may help laboratories negotiate for additional technologists if needed, prepare for Ebola specimens, and manage the demand for laboratory tests for new DOAC anticoagulants.

AB - Objectives: To assess the state of current practice in coagulation laboratories regarding three pressing issues: staffing, handling Ebola specimens, and testing/billing for tests that measure direct oral anticoagulants (DOAC). Methods: A survey and analysis of specialized coagulation laboratories in North America was conducted. Results: Approximately 4,000 special coagulation tests-per-technologist-per-year was rated as either a "good" staffing level or "adequate-but-ideally-need-more" employees. Requiring technologists to perform more than that was rated as an "inadequate" staffing level. For Ebola patients, coagulation testing is mostly performed by point-of-care. Only 26.1% would perform coagulation tests for Ebola specimens within their laboratory (rather than at the bed side or a separate designated space outside the laboratory). Coagulation tests offered for Ebola patients were limited: prothrombin time (63.0% of laboratories), activated partial thromboplastin time (37.0%), D-dimer (13.0%), and fibrinogen (8.7%); 26.1% of laboratories did not offer any coagulation tests for Ebola patients. Approximately 35% of special coagulation laboratories bill for at least one laboratory test for DOACs: 33% bill for an anti-Xa calibrated with rivaroxaban, 17% bill for an anti-Xa calibrated with apixaban, and 27% bill for at least one of several tests for dabigatran. Approximately 48% do not offer any tests for DOACs. Conclusions: These results may help laboratories negotiate for additional technologists if needed, prepare for Ebola specimens, and manage the demand for laboratory tests for new DOAC anticoagulants.

KW - Apixaban

KW - Dabigatran

KW - Direct oral anticoagulant (DOAC)

KW - Ebola

KW - Rivaroxaban

KW - Specialized coagulation laboratory

KW - Staffing

UR - http://www.scopus.com/inward/record.url?scp=85014434088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014434088&partnerID=8YFLogxK

U2 - 10.1093/ajcp/aqw121

DO - 10.1093/ajcp/aqw121

M3 - Article

VL - 146

SP - 378

EP - 383

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -